ATE363483T1 - Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen - Google Patents
Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignenInfo
- Publication number
- ATE363483T1 ATE363483T1 AT04779540T AT04779540T ATE363483T1 AT E363483 T1 ATE363483 T1 AT E363483T1 AT 04779540 T AT04779540 T AT 04779540T AT 04779540 T AT04779540 T AT 04779540T AT E363483 T1 ATE363483 T1 AT E363483T1
- Authority
- AT
- Austria
- Prior art keywords
- disorder
- metabolite
- inhibitor
- symptom
- disease
- Prior art date
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title abstract 4
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title abstract 2
- 239000002207 metabolite Substances 0.000 title abstract 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title abstract 2
- 229940075420 xanthine Drugs 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 208000035475 disorder Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 206010027654 Allergic conditions Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010003645 Atopy Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000022461 Glomerular disease Diseases 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000013901 Nephropathies and tubular disease Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 206010036049 Polycystic ovaries Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 208000018569 Respiratory Tract disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000025609 Urogenital disease Diseases 0.000 abstract 1
- 238000002399 angioplasty Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 238000013171 endarterectomy Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000008991 intestinal motility Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49221803P | 2003-07-31 | 2003-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE363483T1 true ATE363483T1 (de) | 2007-06-15 |
Family
ID=34115611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04779540T ATE363483T1 (de) | 2003-07-31 | 2004-07-29 | Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7312223B2 (enExample) |
| EP (1) | EP1648895B1 (enExample) |
| JP (1) | JP2007500714A (enExample) |
| CN (1) | CN1860119A (enExample) |
| AT (1) | ATE363483T1 (enExample) |
| CA (1) | CA2533715A1 (enExample) |
| DE (1) | DE602004006756T2 (enExample) |
| ES (1) | ES2284056T3 (enExample) |
| MX (1) | MXPA06001195A (enExample) |
| WO (1) | WO2005012303A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| WO2003101992A1 (en) * | 2002-05-31 | 2003-12-11 | Schering Corporation | Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof |
| EP1786428B1 (en) * | 2004-08-17 | 2012-05-16 | The Johns Hopkins University | Pde5 inhibitor compositions and methods for treating cardiac indications |
| KR20090087795A (ko) * | 2008-02-13 | 2009-08-18 | 한양대학교 산학협력단 | 혈관 재협착 예방 및 치료를 위한 약학 조성물 및 이를포함하는 스텐트 |
| CN101747282A (zh) | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
| US20100261737A1 (en) * | 2009-04-10 | 2010-10-14 | Medtronic Vascular, Inc. | Method of Treating Erectile Dysfunction |
| US20140271680A1 (en) | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| WO2013054153A1 (en) | 2011-10-11 | 2013-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nutlin compounds for use in he treatment of pulmonary hypertension |
| CN106770618A (zh) * | 2015-11-20 | 2017-05-31 | 中国康复研究中心 | 一种建立急性缺血性脑卒中特征蛋白的质谱模型的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8906792D0 (en) * | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| IL98559A0 (en) * | 1990-06-21 | 1992-07-15 | Schering Corp | Polycyclic guanine derivatives |
| GB9020959D0 (en) * | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Novel compounds |
| US5409934A (en) * | 1990-12-21 | 1995-04-25 | Smith; David G. | Xanthine derivatives |
| GB9210839D0 (en) * | 1992-05-21 | 1992-07-08 | Smithkline Beecham Plc | Novel compounds |
| CN1118600A (zh) * | 1993-02-26 | 1996-03-13 | 先灵公司 | 2-苄基-多环鸟嘌呤衍生物以及制备它们的方法 |
| US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| WO2003101992A1 (en) | 2002-05-31 | 2003-12-11 | Schering Corporation | Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof |
| AR040233A1 (es) | 2002-05-31 | 2005-03-23 | Schering Corp | Polimorfos inhibidores de xantina fosfodiesterasa v |
-
2004
- 2004-07-29 ES ES04779540T patent/ES2284056T3/es not_active Expired - Lifetime
- 2004-07-29 MX MXPA06001195A patent/MXPA06001195A/es active IP Right Grant
- 2004-07-29 DE DE602004006756T patent/DE602004006756T2/de not_active Expired - Fee Related
- 2004-07-29 US US10/901,574 patent/US7312223B2/en not_active Expired - Fee Related
- 2004-07-29 AT AT04779540T patent/ATE363483T1/de not_active IP Right Cessation
- 2004-07-29 CA CA002533715A patent/CA2533715A1/en not_active Abandoned
- 2004-07-29 EP EP04779540A patent/EP1648895B1/en not_active Expired - Lifetime
- 2004-07-29 JP JP2006522068A patent/JP2007500714A/ja active Pending
- 2004-07-29 WO PCT/US2004/024525 patent/WO2005012303A1/en not_active Ceased
- 2004-07-29 CN CNA2004800280878A patent/CN1860119A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1082739A1 (en) | 2006-06-16 |
| WO2005012303A1 (en) | 2005-02-10 |
| EP1648895B1 (en) | 2007-05-30 |
| CA2533715A1 (en) | 2005-02-10 |
| US20050026939A1 (en) | 2005-02-03 |
| DE602004006756D1 (de) | 2007-07-12 |
| MXPA06001195A (es) | 2006-04-11 |
| DE602004006756T2 (de) | 2008-01-24 |
| JP2007500714A (ja) | 2007-01-18 |
| ES2284056T3 (es) | 2007-11-01 |
| CN1860119A (zh) | 2006-11-08 |
| EP1648895A1 (en) | 2006-04-26 |
| US7312223B2 (en) | 2007-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE363483T1 (de) | Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen | |
| Trinity et al. | Passive leg movement and nitric oxide-mediated vascular function: the impact of age | |
| WO2007089787A3 (en) | Compositions and methods for treating cardiovascular, cerebrovascular and other vascular disease patients | |
| JP7137650B2 (ja) | テトラヒドロイソキノリン誘導体 | |
| WO2005123718A3 (en) | Benzimidazolone carboxylic acid derivatives | |
| JP2020186259A (ja) | 光学活性ピラノクロメニルフェノール誘導体およびそれを含む薬学的組成物 | |
| BRPI0513444A (pt) | antagonistas do receptor da histamina 3 | |
| NZ597222A (en) | Substituted 8-[6-Amino-3-Pyridyl]Xanthines | |
| JP2007500714A5 (enExample) | ||
| JP2007537293A5 (enExample) | ||
| Jitesh et al. | Effect of zumba dance on blood pressure | |
| JPH0273015A (ja) | 置換３，４‐ジヒドロ‐２ｈ‐ベンゾピラン類の肺の閉鎖性機能障害および／または輸出尿路の障害の治療薬としての使用 | |
| EP2094285B1 (de) | Spezialextrakt und seine verwendung zur hemmung des abbaus von cyclischem guanosinmonophosphat (cgmp) | |
| ATE496621T1 (de) | Imidazoä2,1-büthiazole und ihre verwendung als pharmazeutika | |
| Fryer et al. | (−)-(9S)-9-(3-Bromo-4-fluorophenyl)-2, 3, 5, 6, 7, 9-hexahydrothieno [3, 2-b] quinolin-8 (4H)-one 1, 1-dioxide (A-278637), a Novel ATP-Sensitive Potassium Channel Opener: Hemodynamic Comparison to ZD-6169, WAY-133537, and Nifedipine in the Anesthetized Canine | |
| Boss | 20 Years of Medicinal Chemistry–Always Look at the Bright Side (of Life) | |
| WO2006128035A3 (en) | Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension | |
| CN107998140B (zh) | 化合物r1的用途 | |
| Mishra et al. | Auditory, visual and postural reaction time among middle aged type 2 diabetics and healthy individuals–a cross-sectional study | |
| Bofosa et al. | Impact of a program of adapted physical activity on the morphological, physiological, and biological parameters of sedentary hypertensive postmenopausal women | |
| Khabibulina et al. | Impact of metabolic therapy on the state of cerebral hemodynamics in hypoestrogenemia | |
| Trukhanova et al. | Possibilities of Application of Ethylmethylhydroxypyri dine Succinate in the Treatment of Acute Poisoning: a Systematic Literature Review | |
| CN103524431B (zh) | 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用 | |
| Biçki et al. | Effects of Tai Chi on Postural Stability and Balance in Parkinson's Disease | |
| Schnider et al. | EFFECTS OF LOW-DOSE ORO-MUCOSAL DEXMEDETOMIDINE ON SLEEP AND THE SLEEP EEG IN HUMANS: A PHARMACOKINETICS-PHARMACODYNAMICS STUDY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |